Wall Street equity research analysts covering Compugen Ltd. (NASDAQ: CGEN) maintain a consensus rating leaning toward a Strong Buy, with a median twelve-month price target hovering between $4.00 and $5.00 per share. Analysts base these optimistic forward projections on the clinical progression of its immuno-oncology pipeline, strategic pharmaceutical licensing partnerships, milestone payment potentials, and innovative computational drug discovery capabilities.